Efficacy, Safety, and Quality of Treatment Satisfaction of Premixed Human and Analogue Insulin Regimens in a Large Cohort of Type 2 Diabetic Patients: PROGENS BENEFIT Observational Study

International Journal of Endocrinology
Katarzyna NabrdalikJanusz Gumprecht

Abstract

Diabetes is a lifelong course disease, so insulin treatment has to be effective and safe, and patients should be satisfied with it. We aimed to compare efficacy, safety, and quality of treatment satisfaction of human and premixed analogue insulin among 3264 patients (53.58% women) with type 2 diabetes mellitus (T2DM) in a real-life environment. 2493 patients (62.77%) had been assigned to group I where before the inclusion into the study the treatment regimen has been changed from analogue to human premixed insulin and 771 patients (37.23%) to group II where the treatment with insulin analogue remained unchanged. At the end of the study, there was a reduction of HbA1c observed in both of the groups; however, Δ HbA1c was significantly higher in group 1 (-0.599 versus -0.406; P < 0.001 at visit 3 versus visit 1). The number of hypoglycemic episodes during the study observation was insignificantly reduced in both groups. Diabetes treatment satisfaction measured with DTSQ increased at the end of the study and was significantly better in group I compared to group II (P < 0.001). This observational study proved that both human and premixed analogue insulin are effective and safe, and patients are satisfied with the treatment.

References

Jun 1, 1990·Diabetic Medicine : a Journal of the British Diabetic Association·C Bradley, K S Lewis
Feb 1, 2003·Diabetes Research and Clinical Practice·V MattooUNKNOWN Ramadan Study Group
Aug 19, 2007·Diabetes, Obesity & Metabolism·Alan J GarberAndreas Liebl
Nov 27, 2007·Clinical Therapeutics·Robert J LigthelmPaul Valensi
Feb 18, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Chris G Cameron, Heather A Bennett
Mar 31, 2010·Journal of Medical Economics·James L PalmerTrine L Thomsen
Nov 10, 2011·International Journal of Clinical Practice. Supplement·T Danne, J Bolinder
Feb 9, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·M PeyrotP-M Schumm-Draeger
May 10, 2013·Diabetes Research and Clinical Practice·Mary Anne Lim-AbrahanPradana Soewondo
May 24, 2014·Diabetes Care·Mayer B Davidson
Feb 18, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Lisa ElliottTrine Stissing
Oct 4, 2016·Archives of Medical Science : AMS·Magdalena WalickaEdward Franek
Jan 11, 2017·Journal of Diabetes·Payal H MaratheKelly L Close

❮ Previous
Next ❯

Citations

Jan 12, 2020·Journal of Basic and Clinical Physiology and Pharmacology·Arina D PuspitasariBudi Suprapti

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

IMPROVE
ASEAN
PROGENS BENEFIT
PRESENT
Statsoft Statistica

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.